Telbivudine Therapy in HBeAg-positive Pregnant Women to Prevent Mother-to-infant Transmission of HBV
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
Infants of hepatitis B virus (HBV)-infected mothers with positive hepatitis B e antigen
(HBeAg) have an increased risk of becoming infected with HBV. This study will determine
whether telbivudine among both hepatitis B surface antigen (HBsAg) and HBeAg positive
pregnant women during the third trimester, in addition to standard immunoprophylaxis in
infants, will be more effective than standard immunoprophylaxis alone at preventing HBV
infections in these infants.
Phase:
Phase 4
Details
Lead Sponsor:
Yi-Hua Zhou
Collaborators:
Fourth People's Hospital of Zhenjiang, China Kunshan First People Hospital Taixing People's Hospital Wuxi Maternal and Child Health Hospital